Allogeneic stem cell transplantation and novel therapies: is the treatment paradigm for younger patients with chronic lymphocytic leukemia changing?

被引：0

作者：

Volpetti, Stefano ^{[1
]}

Lucchini, Elisa ^{[1
]}

Mazzucco, Maddalena ^{[1
]}

Perali, Giulia ^{[1
]}

Frisoli, Sara ^{[1
]}

Patriarca, Francesca ^{[1
]}

Zaja, Francesco ^{[1
]}

Fanin, Renato ^{[1
]}

机构：

[1] Azienda Sanit Univ Integrata SM Misericordia, Clin Ematol, DISM, Udine, Italy

来源：

DRUGS AND CELL THERAPIES IN HEMATOLOGY | 2015年 / 3卷 / 04期

关键词：

CLL; Ibrutinib; Idelalisib; Venetoclax; allogeneic stem cell transplant;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment of chronic lymphocytic leukemia (CLL) is one of the most evolving fields of oncologic hematology. In the past few years several novel drugs, in particular B-cell receptor (BCR) and BCL-2 inhibitors, have been investigated in relapsed/refractory (R/R) and high-risk (HR) CLL patients, demonstrating impressive outcomes. These new agents may compete the use of allogeneic hematopoietic stem cell transplantation (HSCT), which at present is considered the only potentially curative treatment option in this setting of patients; nevertheless, transplant-related toxicity remains a relevant issue. For these reasons, the development of effective, well-tolerated agents, able to overcome the classical pathways involved in CLL refractoriness such as TP53 mutation or 17p chromosome (del(17p)), represents a challenge for consolidated treatment algorithms, requiring a critical review on the basis of new evidences. In this paper first we summarize clinical data regarding BCR and BCL-2 inhibitors and HSCT in CLL, then we discuss how these new drugs may change the actual therapeutic paradigm of R/R and HR-CLL.

引用

页码：226 / 236

页数：11

共 49 条

[1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[2]

[Anonymous], BLOOD

[3] BH3 Mimetics: Status of the Field and New Developments [J].

Billard, Christian .

MOLECULAR CANCER THERAPEUTICS, 2013, 12 (09) :1691-1700

[4] Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies [J].

Boettcher, Sebastian ;

Ritgen, Matthias ;

Dreger, Peter .

BLOOD REVIEWS, 2011, 25 (02) :91-96

[5] Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome [J].

Brown, J. R. ;

Kim, H. T. ;

Armand, P. ;

Cutler, C. ;

Fisher, D. C. ;

Ho, V. ;

Koreth, J. ;

Ritz, J. ;

Wu, C. ;

Antin, J. H. ;

Soiffer, R. J. ;

Gribben, J. G. ;

Alyea, E. P. .

LEUKEMIA, 2013, 27 (02) :362-369

[6] The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia [J].

Brown, Jennifer R. ;

Barrientos, Jacqueline C. ;

Barr, Paul M. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Anh Tran ;

Clow, Fong ;

James, Danelle F. ;

Graef, Thorsten ;

Friedberg, Jonathan W. ;

Rai, Kanti ;

O'Brien, Susan .

BLOOD, 2015, 125 (19) :2915-2922

[7] Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia [J].

Brown, Jennifer R. ;

Byrd, John C. ;

Coutre, Steven E. ;

Benson, Don M. ;

Flinn, Ian W. ;

Wagner-Johnston, Nina D. ;

Spurgeon, Stephen E. ;

Kahl, Brad S. ;

Bello, Celeste ;

Webb, Heather K. ;

Johnson, Dave M. ;

Peterman, Sissy ;

Li, Daniel ;

Jahn, Thomas M. ;

Lannutti, Brian J. ;

Ulrich, Roger G. ;

Yu, Albert S. ;

Miller, Langdon L. ;

Furman, Richard R. .

BLOOD, 2014, 123 (22) :3390-3397

[8] Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study [J].

Burger, Jan A. ;

Keating, Michael J. ;

Wierda, William G. ;

Hartmann, Elena ;

Hoellenriegel, Julia ;

Rosin, Nathalie Y. ;

de Weerdt, Iris ;

Jeyakumar, Ghayathri ;

Ferrajoli, Alessandra ;

Cardenas-Turanzas, Marylou ;

Lerner, Susan ;

Jorgensen, Jeffrey L. ;

Nogueras-Gonzalez, Graciela M. ;

Zacharian, Gracy ;

Huang, Xuelin ;

Kantarjian, Hagop ;

Garg, Naveen ;

Rosenwald, Andreas ;

O'Brien, Susan .

LANCET ONCOLOGY, 2014, 15 (10) :1090-1099

[9] Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Shaw, Yun ;

Bilotti, Elizabeth ;

Zhou, Cathy ;

James, Danelle F. ;

O'Brien, Susan .

BLOOD, 2015, 125 (16) :2497-2506

[10] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

← 1 2 3 4 5 →